VanEck Vectors Biotech ETF Stock Forecast, Price & News

+1.47 (+0.68 %)
(As of 09/16/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume11,643 shs
Average Volume14,253 shs
Market Capitalization$627.92 million
P/E RatioN/A
Dividend Yield0.28%
30 days | 90 days | 365 days | Advanced Chart
Receive BBH News and Ratings via Email

Sign-up to receive the latest news and ratings for VanEck Vectors Biotech ETF and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer Van Eck
Fund NameVanEck Vectors Biotech ETF
Tax ClassificationRegulated Investment Company
Inception Date12/20/2011
Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin

Fund Focus

Asset ClassEquity
BenchmarkMarket Vectors US Listed Biotech 25 Index
FocusHealth Care
Development LevelDeveloped Markets

Fund Statistics

Assets Under Management$1.92 billion
Average Daily Volume$14,048.50

ETF Expenses

Management Fee0.35%
Other Expenses0.04%
Total Expenses0.39%
Fee Waiver-0.04%
Net Expenses0.35%

Administrator, Advisor and Custodian

AdministratorVan Eck Associates Corporation
AdvisorVan Eck Associates Corporation
CustodianThe Bank of New York Mellon Corporation
DistributorVan Eck Securities Corporation
Transfer AgentThe Bank of New York Mellon Corporation
Lead Market MakerVirtu Financial

Geographic Exposure of BBH

Currency Exposure of BBH

Sector Exposure of BBH

Industry Exposure of BBH

speech bubbles
speech bubbles

VanEck Vectors Biotech ETF (NASDAQ:BBH) Frequently Asked Questions

What stocks does MarketBeat like better than VanEck Vectors Biotech ETF?

Wall Street analysts have given VanEck Vectors Biotech ETF a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VanEck Vectors Biotech ETF wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting VanEck Vectors Biotech ETF?

VanEck Vectors Biotech ETF saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 32,700 shares, an increase of 144.0% from the July 29th total of 13,400 shares. Based on an average daily trading volume, of 16,600 shares, the days-to-cover ratio is currently 2.0 days.
View VanEck Vectors Biotech ETF's Short Interest

How has VanEck Vectors Biotech ETF's stock been impacted by COVID-19?

VanEck Vectors Biotech ETF's stock was trading at $126.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BBH stock has increased by 70.9% and is now trading at $216.75.
View which stocks have been most impacted by COVID-19

How often does VanEck Vectors Biotech ETF pay dividends? What is the dividend yield for VanEck Vectors Biotech ETF?

VanEck Vectors Biotech ETF announced an annual dividend on Friday, December 18th. Shareholders of record on Tuesday, December 22nd will be paid a dividend of $0.608 per share on Monday, December 28th. This represents a dividend yield of 0.35%. The ex-dividend date is Monday, December 21st. This is a positive change from VanEck Vectors Biotech ETF's previous annual dividend of $0.42.
View VanEck Vectors Biotech ETF's dividend history

Is VanEck Vectors Biotech ETF a good dividend stock?

VanEck Vectors Biotech ETF pays an annual dividend of $0.61 per share and currently has a dividend yield of 0.28%.
View VanEck Vectors Biotech ETF's dividend history.

Who are some of VanEck Vectors Biotech ETF's key competitors?

What other stocks do shareholders of VanEck Vectors Biotech ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VanEck Vectors Biotech ETF investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), (SNY), Intel (INTC), Micron Technology (MU), Cidara Therapeutics (CDTX), Quest Diagnostics (DGX), (MRNA) and Novavax (NVAX).

What is VanEck Vectors Biotech ETF's stock symbol?

VanEck Vectors Biotech ETF trades on the NASDAQ under the ticker symbol "BBH."

Who are VanEck Vectors Biotech ETF's major shareholders?

VanEck Vectors Biotech ETF's stock is owned by many different retail and institutional investors. Top institutional investors include Goldman Sachs Group Inc. (4.10%), Morgan Stanley (2.21%), Morgan Stanley (2.19%), Royal Bank of Canada (1.89%), Bank of America Corp DE (1.12%) and Mogy Joel R Investment Counsel Inc. (1.03%).

Which major investors are selling VanEck Vectors Biotech ETF stock?

BBH stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, BHF RG Capital Inc., Goldman Sachs Group Inc., Bank of America Corp DE, Morgan Stanley, Morgan Stanley, Advisor Group Holdings Inc., and First National Bank of South Miami.

Which major investors are buying VanEck Vectors Biotech ETF stock?

BBH stock was acquired by a variety of institutional investors in the last quarter, including Flow Traders U.S. LLC, Wealthspire Advisors LLC, Prudential PLC, Millennium Management LLC, Royal Bank of Canada, Mogy Joel R Investment Counsel Inc., Envestnet Asset Management Inc., and LPL Financial LLC.

How do I buy shares of VanEck Vectors Biotech ETF?

Shares of BBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VanEck Vectors Biotech ETF's stock price today?

One share of BBH stock can currently be purchased for approximately $216.75.

How much money does VanEck Vectors Biotech ETF make?

VanEck Vectors Biotech ETF has a market capitalization of $627.92 million.

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.